Research Study to Investigate How Well Semaglutide Tablets Taken Once Daily Work in People Who Are Overweight or Living With Obesity (OASIS 1)

PHASE3CompletedINTERVENTIONAL
Enrollment

667

Participants

Timeline

Start Date

September 13, 2021

Primary Completion Date

March 24, 2023

Study Completion Date

May 12, 2023

Conditions
ObesityOverweight
Interventions
DRUG

Oral semaglutide

Participants will receive a daily dose of oral semaglutide.

DRUG

Placebo (semaglutide)

Oral placebo (semaglutide) once daily. Planned treatment duration will be 68 weeks.

Trial Locations (51)

2650

Hvidovre Hospital Endokrinologisk forsknings afsnit 159, Hvidovre

2900

Center for Klinisk Metabolisk Forskning, Hellerup

4600

Sjællands Universitetshospital, Køge

22041

Diabetes Zentrum Wandsbek Berufsausuebungsgemeinschaft GbR, Hamburg

22206

Washington Cntr Weight Mgmt, Arlington

23758

RED-Institut für medizinische Forschung und Fortbildung GmbH, Oldenburg in Holstein

28401

Accellacare, Wilmington

28630

Les Hopitaux de Chartres-Hopital Louis Pasteur, Le Coudray

33324

Clinical Trial Res Assoc,Inc, Plantation

33600

Centre Hospitalier Universitaire de Bordeaux-Hopital Haut Leveque-2, Pessac

35233

Univ of Alabama Birmingham, Birmingham

40620

StudyCor, Jyväskylä

44800

Centre Hospitalier Universitaire de Nantes-Hopital Nord Laennec-1, Saint-Herblain

45136

InnoDiab Forschung GmbH, Essen

46260

Midwest Inst For Clin Res, Indianapolis

60220

Seinäjoen keskussairaala, Seinäjoki

66780

Praxis Dr. med. Wenzl-Bauer, Rehlingen-Siersburg

69200

Centre de Recherche Clinique Portes Du Sud, Vénissieux

70378

Erlinger, Stuttgart

71200

Fondation Hôtel-Dieu, Le Creusot

Groupe Sos Sante-Hopital Le Creusot-Hotel Dieu-2, Le Creusot

75230

Velocity Clinical Res-Dallas, Dallas

88239

Zentrum für klinische Studien Allgäu Oberschwaben, Wangen

90057

Velocity Clin Res Wstlke, Los Angeles

96814

East West Med Res Inst, Honolulu

98502

Capital Clin Res Ctr,LLC, Olympia

117292

National Medical Research Center of Endocrinology, Moscow

119034

Endocrinological Dispensary of Department of healthcare ser., Moscow

127486

Federal Bureau for Medical and Social Expertise, Moscow

140091

"LLC Clinic of new technologies in Medicine", Dzerzhinskiy

190013

"Joint Stock Company Polyclinic Complex", Saint Petersburg

194291

Leningrad Regional Clinical Hospital, Saint Petersburg

620075

"Joint Stock Company Medical technologies", Yekaterinburg

625023

Tumen State Medical University, Tyumen

19104-3317

The University of Penn Center, Philadelphia

22601-3834

Selma Medical Associates, Winchester

V3Z 2N6

Ocean West Research Clinic, Surrey

E1G 1A7

G.A. Research Associates Ltd., Moncton

B3H 1V7

Nova Scotia Health Authority, Halifax

L8L 5G8

Wharton Med Clin Trials, Hamilton

L8M 1K7

Hamilton Med Res Group, Hamilton

00014

Obesity Research Unit, Helsinki

06679

Milek, Hohenmölsen, Hohenmölsen

260-8677

Chiba University Hospital_Diabetes, Metabolism and Endocrinology, Chiba-shi, Chiba

101-0065

Suidoubashi Medical Clinic, Chiyoda-ku, Tokyo

169-0072

Higashi-shinjuku clinic, Tokyo

20-538

NZOZ Przychodnia Specjalistyczna Medica, Lublin

15-281

Gabinet Leczenia Otylosci i Chorob Dietozaleznych, Bialystok

81-338

Centrum Medyczne Pratia Gdynia, Gdynia

60-589

Centrum Zdrowia Metabolicznego, Poznan

90-338

Centrum Terapii Wspolczesnej, Lodz

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY